<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605978</url>
  </required_header>
  <id_info>
    <org_study_id>CL2-95011-001</org_study_id>
    <secondary_id>2020-001526-59</secondary_id>
    <nct_id>NCT04605978</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients</brief_title>
  <official_title>A Phase IIa Efficacy and Safety Trial With Intravenous S95011 in Primary Sjögren's Syndrome Patients: An International, Multicentre, Randomised, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ADIR, a Servier Group company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of multiple intravenous infusions of S95011&#xD;
      compared to placebo in reducing disease activity in patients with primary Sjögren's syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ESSDAI total score</measure>
    <time_frame>From baseline to week 13</time_frame>
    <description>Efficacy criterion Eular Sjögren Syndrome Disease Activity index (ESSDAI) is a physician-administered clinical index which has been validated to objectively assess systemic manifestations in Primary Sjögren's Syndrome patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ESSDAI score by domain and total score</measure>
    <time_frame>At baseline, week 4 and week 13</time_frame>
    <description>Efficacy criterion Eular Sjögren Syndrome Disease Activity index (ESSDAI) is a physician-administered clinical index which has been validated to objectively assess systemic manifestations in Primary Sjögren's Syndrome patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESSPRI score by symptom and total score</measure>
    <time_frame>At baseline, week 4 and week 13</time_frame>
    <description>Efficacy criterion EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is an index designed to measure patients' symptoms in primary Sjögren's Syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-36)</measure>
    <time_frame>At baseline and week 13</time_frame>
    <description>Efficacy criterion The Short Form (SF-36) Health Survey is a 36-item, patient-reported survey of patient health to asses QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue (MFI)</measure>
    <time_frame>At baseline and week 13</time_frame>
    <description>Efficacy criterion Modified Fatigue Impact Scale (MFI) is a 20-item survey to evaluate ﬁve dimensions of fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global assessment (PhGA) of the disease activity</measure>
    <time_frame>At baseline and week 13</time_frame>
    <description>Efficacy criterion Physician's global assessment (PhGA) of the disease activity is a 0 to 10 numerical rating scale (NRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment (PGA) of the disease activity</measure>
    <time_frame>At baseline and week 13</time_frame>
    <description>Efficacy criterion Patient's global assessment (PGA) of the disease activity is a 0 to 10 numerical rating scale (NRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Through study completion, up to Week 28</time_frame>
    <description>Safety criterion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Primary Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>S95011 concentrate for solution for infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S95011 is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S95011 Placebo concentrate for solution for infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>S95011 placebo is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S95011 concentrate for solution for infusion</intervention_name>
    <description>IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.</description>
    <arm_group_label>S95011 concentrate for solution for infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo concentrate for solution for infusion</intervention_name>
    <description>IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.</description>
    <arm_group_label>S95011 Placebo concentrate for solution for infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of primary Sjögren's Syndrome based on 2016 American College of&#xD;
             Rheumatology-EULAR criteria&#xD;
&#xD;
          2. ESSDAI total score ≥ 6 during screening, with at least 6 points scored within the 7&#xD;
             following domains: constitutional, lymphadenopathy, glandular, articular, cutaneous,&#xD;
             hematologic and biologic,&#xD;
&#xD;
          3. Positive anti-Sjögren's Syndrome A (Ro) antibodies or anti-nuclear antibodies (ANA) ≥&#xD;
             1:320 or rheumatoid factor (RF) &gt;20 IU/ml during screening period, measured in a&#xD;
             central laboratory&#xD;
&#xD;
          4. Stimulated whole salivary flow rate &gt; 0 mL/minute&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior administration within the timeframe described in the protocol of any of the&#xD;
             following:&#xD;
&#xD;
               -  Belimumab,&#xD;
&#xD;
               -  Rituximab or other B cell depleting agents,&#xD;
&#xD;
               -  Abatacept,&#xD;
&#xD;
               -  Tumor necrosis factor inhibitors,&#xD;
&#xD;
               -  Tocilizumab,&#xD;
&#xD;
               -  Cyclophosphamide,&#xD;
&#xD;
               -  Cyclosporine (except for eye drops), tacrolimus, sirolimus, mycophenolate mofetil&#xD;
                  (MMF), azathioprine, or leflunomide.&#xD;
&#xD;
          2. Meeting any of the following conditions:&#xD;
&#xD;
               -  Corticosteroids: &gt; 10 mg/day oral prednisone (or equivalent) within 4 weeks prior&#xD;
                  to randomisation (W000); Any change or initiation of new dose of oral prednisone&#xD;
                  (or equivalent) within 4 weeks prior to randomisation (W000); Intramuscular, IV,&#xD;
                  or intra-articular corticosteroids within 4 weeks prior to randomisation (W000);&#xD;
                  Any change or initiation of new dose of topical corticosteroids within 2 weeks&#xD;
                  prior to randomisation (W000),&#xD;
&#xD;
               -  Antimalarials: any change or initiation of new dose of antimalarials (e.g.&#xD;
                  chloroquine, hydroxychloroquine, quinacrine) within 16 weeks prior to&#xD;
                  randomisation (W000),&#xD;
&#xD;
               -  Methotrexate: &gt; 25 mg/week of methotrexate; any initiation or change of dose of&#xD;
                  methotrexate within 12 weeks prior to randomisation (W000); any change in route&#xD;
                  of administration within 4 weeks prior to randomisation (W000),&#xD;
&#xD;
               -  Non-steroidal anti-inflammatory drugs (NSAIDs): Any change or initiation of new&#xD;
                  dose of regularly scheduled NSAIDs within 2 weeks prior to randomisation (W000),&#xD;
&#xD;
               -  Cevimeline or pilocarpine and cyclosporine eye drops (Restasis) and lifitegrast:&#xD;
                  any increase or initiation of new doses within 2 weeks prior to randomisation&#xD;
                  (W000).&#xD;
&#xD;
          3. Secondary Sjögren's Syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Institut de Recherches Internationales Servier Clinical Studies Department</last_name>
    <phone>+33 1 55 72 43 66</phone>
    <email>clinical.trial.management@servier.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Attune Health</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>RASF</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tufts School of Dental Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital Rheumatology Unit</name>
      <address>
        <city>Woodville</city>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU-Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen Medizinische Klinik 3 Rheumatologie und Immunologie</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg Department Innere Medizin Klinik für Rheumatologie und Klinische Immunologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover Klinik für Rheumatologie und Immunologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos és Egészségtudományi Centrum Belgyógyászat C épület - Klinikai Immunológiai Tanszék</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Békés Megyei Központi Kórház, Pándy Kálmán Tagkórház, Infektológia-Hepatológia</name>
      <address>
        <city>Gyula</city>
        <zip>57000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vita Verum Medical Bt. Berényi u. 72-100. 95. számú épület 16. Rendelő</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CLINICA SAGRADA FAMILIA Servicio de Reumatología y Unidad de Ensayos Clínicos</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. de Mérida Unidad de Reumatología</name>
      <address>
        <city>Mérida</city>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CLINICAL GAIAS SANTIAGO Servicio de Reumatología</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Luisa Quirón Salud Servicio de Reumatología</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital, University Hospital Southampton NHS Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.servier.com/</url>
    <description>Find Results on Servier Clinical Trial Data website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sjögren</keyword>
  <keyword>Sjögren's Syndrome</keyword>
  <keyword>Autoimmune disease</keyword>
  <keyword>Systemic</keyword>
  <keyword>Xerostomia</keyword>
  <keyword>xerophthalmia</keyword>
  <keyword>Salivary gland disease</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Joint disease</keyword>
  <keyword>Monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.&#xD;
Access can be requested for all interventional clinical studies:&#xD;
used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).&#xD;
where Servier is the Marketing Authorization Holder (MAH).&#xD;
The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.&#xD;
In addition, access can be requested for all interventional clinical studies in patients:&#xD;
sponsored by Servier&#xD;
with a first patient enrolled as of 1 January 2004 onwards&#xD;
for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After Marketing Authorisation in EEA or US if the study is used for the approval.</ipd_time_frame>
    <ipd_access_criteria>Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.</ipd_access_criteria>
    <ipd_url>https://clinicaltrials.servier.com/</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>study-level clinical trial data</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

